| Identification | Back Directory | [Name]
6-Benzothiazolecarboxylic acid, 2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methyl]-2-methyl-1-piperazinyl]-4-methoxy- | [CAS]
2226133-29-3 | [Synonyms]
HPG1860
6-Benzothiazolecarboxylic acid, 2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methyl]-2-methyl-1-piperazinyl]-4-methoxy- | [Molecular Formula]
C27H26Cl2N4O4S | [MOL File]
2226133-29-3.mol | [Molecular Weight]
573.49 |
| Chemical Properties | Back Directory | [Boiling point ]
730.3±70.0 °C(Predicted) | [density ]
1.442±0.06 g/cm3(Predicted) | [solubility ]
DMSO: Sparingly soluble: 1-10 mg/ml
Ethanol: Sparingly soluble: 1-10 mg/ml | [pka]
3.20±0.30(Predicted) |
| Hazard Information | Back Directory | [Uses]
HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH)[1]. | [References]
[1] Mo C, et al. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis. Journal of medicinal chemistry. 2023, 66(14), 9363–9375. DOI:10.1021/acs.jmedchem.3c00456 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|